Prescribing patterns in patients with obsessive-compulsive disorder: Retrospective, single-center study.
benzodiazepine
obsessive compulsive disorder
pharmacotherapy
prescribing patterns
selective‐serotonin reuptake inhibitors
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
revised:
23
04
2024
received:
19
10
2023
accepted:
26
04
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
11
5
2024
Statut:
aheadofprint
Résumé
Obsessive-compulsive disorder (OCD) is marked by a high rate of treatment resistance. Patients are often left trialing medications within multiple drug classes with little response, causing heterogeneity to emerge in prescribing patterns. This analysis seeks to investigate the selection and dosing of the pharmacotherapy utilized, to portray an overview of prescribing trends in the United States. This retrospective, single center, review of electronic medical records investigated the pharmacotherapy utilization of patients with a primary diagnosis of OCD. Two hundred and ninety-five patients who received OCD treatment at an urban, academic medical center were included in the study. Patients were included in the review if they were at least eighteen years of age and were assigned a diagnosis of OCD according to DSM-5 criteria. Psychotropic pharmacotherapy was integrated into the care of 93% of patients. Selective serotonin reuptake inhibitors were the most utilized medication class at 85% followed by benzodiazepines (47%) and second-generation antipsychotics (37%). Tricyclic antidepressants and first-generation antipsychotics were the two medication classes utilized the least at 13% and 2% respectively. Additionally, mood stabilizers and serotonin-norepinephrine reuptake inhibitors were utilized at rates of 8% and 16%, respectively. Evidence-based treatment guidelines are being followed with varying augmentation strategies widely prevalent, thus displaying the heterogeneity in treating OCD. A high rate of benzodiazepine utilization highlights a practice trend with potential ties to clinical factors, such as the latency to treatment effect of other first-line pharmacotherapies. Future prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that contribute to the variation in prescribing practices and whether these variations influence treatment outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2900Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
A.P.A. (2007). Treatment of patients with obsessive–compulsive disorder [online]. American Psychiatric Association. Retrieved June 6, 2021, from http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_10.aspx
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., Malizia, A., McCrone, P., Nabarro, D., O’Neill, C., Scott, J., van der Wee, N., & Wittchen, H. U. (2014). Evidence‐based pharmacological treatment of anxiety disorders, post‐traumatic stress disorder and obsessive–compulsive disorder: A revision of the 2005 guidelines from the British association for psychopharmacology. Journal of Psychopharmacolgy, 28(5), 403–439. https://doi.org/10.1177/0269881114525674
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H. J., Wfsbp Task Force On Treatment Guide, Zohar, J., Kasper, S., Möller, H. J., & Wfsbp Task Force On Treatment Guide (2008). World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post‐traumatic stress disorders—First revision. World Journal of Biological Psychiatry, 9(4), 248–312. https://doi.org/10.1080/15622970802465807
Blanco, C., Olfson, M., Stein, D. J., Simpson, H. B., Gameroff, M. J., & Narrow, W. H. (2006). Treatment of obsessive‐compulsive disorder by US psychiatrists. The Journal of Clinical Psychiatry, 67(6), 946–951. https://doi.org/10.4088/jcp.v67n0611
Bloch, McG., Weisenberger, L.‐W., Landeros‐Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010). Meta‐analysis of the dose‐response relationship of SSRI in obsessive‐compulsive disorder. Molecular Psychiatry, 15(8), 850–855. https://doi.org/10.1038/mp.2009.50
Brakoulias, V., Starcevic, V., Belloch, A., Dell'Osso, L., Ferrão, Y. A., Fontenelle, L. F., Lochner, C., Marazziti, D., Martin, A., Matsunaga, H., Miguel, E. C., Reddy, Y. C. J., do Rosário, M. C., Shavitt, R. G., Sundar, A. S., Stein, D. J., & Viswasam, K. (2016). International prescribing practices in obsessive‐compulsive disorder (OCD). Human Psychopharmacology, 31(4), 319–324. https://doi.org/10.1002/hup.2541
Dell'Osso, B., Camuri, G., Benatti, B., Buoli, M., & Altamura, A. C. (2013). Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive‐compulsive disorder. Early Intervention in Psychiatry, 7(4), 374–380. https://doi.org/10.1111/eip.12016
Denys, D. (2006). Pharmacotherapy of obsessive‐compulsive disorder and obsessive‐compulsive spectrum disorders. Psychiatric Clinics of North America, 29(2), 553–584. xi. https://doi.org/10.1016/j.psc.2006.02.013
Drug Enforcement Administration. (2023). Benzodiazepines (street names: Benzos, downers, nerve pills, tranks). https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf
Fiorillo, A., Dell'Osso, B., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Del Vecchio, V., Di Nicola, M., Ferrari, S., Goracci, A., Iasevoli, F., Luciano, M., Martinotti, G., Nanni, M. G., Nivoli, A., Pinna, F., Poloni, N., Pompili, M., …, & Volpe, U. (2015). Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatric Disease and Treatment, 11, 1885–1909. https://doi.org/10.2147/ndt.s83130
Issari, Y., Jakubovski, E., Bartley, C., Pittenger, C., & Bloch, M. (2016). Early onset of response with selective serotonin reuptake inhibitors in obsessive‐compulsive disorder: A meta‐analysis. The Journal of Clinical Psychiatry, 77(05), e605–e611. https://doi.org/10.4088/JCP.14r09758
Kirkwood, C. K., Melton, S. K., & Wells, B. G. (2017). Posttraumatic stress disorder and obsessive‐compulsive disorder. In J. T. DiPiro, R. L. Talbert, G. C. Yee, (Eds.), Pharmacotherapy: A pathophysiologic approach (10th ed., pp. 1099–1109). McGraw‐Hill.
Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S. (2010). Second‐generation antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews, (12), CD008141. https://doi.org/10.1002/14651858.CD008141.pub2
Murray, C., & Lopez, A. (1996). The global burden of diseases: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (p. 325). Boston: Harvard School of Public Health.
N.I.C.E. (2005). Obsessive–compulsive disorder: Core interventions in the treatment of obsessive–compulsive disorder and body dysmorphic disorder. [Online]. London National Institute for Health and Clinical Excellence (NICE). Retrieved March 28, 2024, from www.nice.org.uk/guidelines.aspx?o=guide‐lines.completed
Poppe, C., Müller, S. T., Greil, W., Walder, A., Grohmann, R., & Stübner, S. (2016). Pharmacotherapy for obsessive compulsive disorder in clinical practice – Data of 842 inpatients from the International AMSP Project between 1994 and 2012. Journal of Affective Disorders, 200, 89–96. https://doi.org/10.1016/j.jad.2016.04.035
Schreurs, K., Luermans, H., Luermans, J., Haack, M. J., & Griez, E. (2005). Obsessive‐compulsive disorder: A critical review of therapeutic perspectives. Acta Psychiatrica Scandinavica, 111(4), 261–271. https://doi.org/10.1111/j.1600‐0447.2004.00502.x
Sharma, E., Sharma, L. P., Balachander, S., Lin, B., Manohar, H., Khanna, P., Lu, C., Garg, K., Thomas, T. L., Au, A. C. L., Selles, R. R., Højgaard, D. R. M. A., Skarphedinsson, G., & Stewart, S. E. (2021). Comorbidities in obsessive‐compulsive disorder across the lifespan: A systematic review and meta‐analysis. Frontiers in Psychiatry, 12, 703701. https://doi.org/10.3389/fpsyt.2021.703701
Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P., Fineberg, N. A., Salkovskis, P., Welton, N. J., Baxter, H., Kessler, D., Churchill, R., & Lewis, G. (2016). Pharmacological and psychotherapeutic interventions for management of obsessive‐compulsive disorder in adults: A systematic review and network meta‐analysis. The Lancet Psychiatry, 3(8), 730–739. https://doi.org/10.1016/S2215‐0366(16)30069‐4
Starcevic, V., Berle, D., do Rosário, M. C., Brakoulias, V., Ferrão, Y. A., Viswasam, K., Shavitt, R., Miguel, E., & Fontenelle, L. F. (2016). Use of benzodiazepines in obsessive‐compulsive disorder. International Clinical Psychopharmacology, 31(1), 27–33. https://doi.org/10.1097/YIC.0000000000000100
Tastevin, M., Spatola, G., Régis, J., Lançon, C., & Richieri, R. (2019). Deep brain stimulation in the treatment of obsessive‐compulsive disorder: Current perspectives. Neuropsychiatric Disease and Treatment, 15, 1259–1272. https://doi.org/10.2147/ndt.s178207
Van, A., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., Marazziti, D., Menchon, J. M., Nicolini, H., Pallanti, S., Stein, D. J., & Zohar, J. (2014). Pharmacological treatment strategies in obsessive compulsive disorder: A cross‐sectional view in nine international OCD centers. Journal of Psychopharmacology, 28(6), 596–602. https://doi.org/10.1177/0269881113517955
Van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023). Treatment‐resistant OCD: Pharmacotherapies in adults. Comprehensive Psychiatry, 120, 152352. https://doi.org/10.1016/j.comppsych.2022.152352